ABSTRACT Introduction: The remission induction treatment for acute myeloid leukemia (AML) has remained unchanged in the resource-limited setting in the Philippines. AML treatment consists of induction chemotherapy followed by high dose consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. In the Philippines, the Filipino household bears the burden of health care cost of hospitalization expenditure. Insights into the treatment costs becomes an essential requirement as these guides the allocation of resources to scheme health programs. Method: This study involved a retrospective cohort analysis of AML patients who underwent treatment for AML. Review of the statements of account per admission per patient during treatment for remission induction, consolidation, relapsed and refractory disease and best supportive care from 2017 to 2019. Of the 251 eligible patients, 190 patients were included. Result: The mean healthcare expenditure for remission induction chemotherapy (Phase 1) was US $2, 504.78 (Php 125,239.29). While 3 to 4 cycles of consolidation chemotherapy cost an average of US $3,222.72 (Php 162,103.20). For patients who had relapsed and refractory disease, an additional mean cost of US $3,163.32 (Php 159,115.28) and US $2, 914.72 (Php 146,610.55) were incurred, respectively. The average cost of palliative care was US $1,687.00 (Php 84,856.59). Conclusion: The cost of chemotherapy and other therapeutics bear most of the weight of the direct healthcare cost. The cost of AML treatment represents a significant economic burden for patients and the institution. The cost increases as patients proceed through subsequent lines of treatment for induction failure. Existing subsidy for health insurance benefits could still be improved for appropriate source allocation of resources. Introduction (AML resourcelimited resource limited Philippines transplantation programs Method 201 2019 25 19 included Result Phase 1 2 $2 50478 504 78 504.7 Php 125,239.29. 12523929 125,239.29 . 125 239 29 125,239.29) 322272 222 72 $3,222.7 162,103.20. 16210320 162,103.20 162 103 20 162,103.20) 316332 163 32 $3,163.3 159,115.28 15911528 159 115 28 91472 914 914.7 146,610.55 14661055 146 610 55 incurred respectively 168700 687 00 $1,687.0 84,856.59. 8485659 84,856.59 84 856 59 84,856.59) Conclusion institution failure $ 5047 50 7 504. 1252392 125,239.2 12 23 32227 22 $3,222. 1621032 162,103.2 16 10 31633 $3,163. 159,115.2 1591152 15 11 9147 91 914. 146,610.5 1466105 14 61 5 16870 68 0 $1,687. 848565 84,856.5 8 85 125239 125,239. 3222 $3,222 162103 162,103. 3163 $3,163 159,115. 159115 9 146,610. 146610 6 1687 $1,687 84856 84,856. 12523 125,239 322 $3,22 16210 162,103 316 $3,16 159,115 15911 146,610 14661 168 $1,68 8485 84,856 1252 125,23 $3,2 1621 162,10 31 $3,1 159,11 1591 146,61 1466 $1,6 848 84,85 125,2 $3, 162,1 159,1 146,6 $1, 84,8 125, $3 162, 159, 146, $1 84,

ABSTRACT Introduction: Hematologic abnormalities are common in HIV and involve all blood cell lineages. A study on cytopenias, as correlated with disease progression, can be valuable in resource-limited settings. This study aimed to determine the hematologic profile of HIV patients and its association with CD4 count and antiretroviral (ARV) treatment. Methods: This is a retrospective cohort study involving adult Filipino HIV patients with complete blood count (CBC) and CD4 count determinations prior to the initiation of ARV treatment and after ≥6 months of ARV treatment. Logistic regression was performed to determine the association between cytopenias and a CD4 count <200 cells/μL. Results: The study included 302 patients. Anemia was the most common cytopenia. Anemia and leukopenia were associated with an increased likelihood of having a CD4 count <200 cells/μL in ARV-naïve patients. In ARV-treated patients, leukopenia was associated with an increased probability of having a CD4 count <200 cells/μL. An increase in hemoglobin, white blood cell (WBC) and platelet counts was observed after ≥6 months of ARV treatment. Conclusion: Anemia and leukopenia can be used as markers of immune status in HIV-infected individuals and improvement in the CBC parameters can be used to assess response to ARV treatment. Routine monitoring of hematologic parameters is recommended.